Associate Director, HEOR & Access

Indeg Sly

She has led the economic development of numerous HTA submissions, predominantly submissions to NICE. Worked on >20 cost-effectiveness models including discrete event simulations, in addition to early CE modelling projects. Indeg has conducted extensive analyses in R including patient-level propensity score matching and survival analysis.

Indeg has over 8 years’ experience in HEOR and market access across consultancy and the NHS.

Contact Indeg

Key facts

Has led clinical advisory boards, Delphi panels and KOL interviews

She has contributed to the development of a utility vignette study.

Worked on multi million commercial deals between the pharma industry and the NHS

Including BIT, MAA, CDF, HST and innovative pricing deals. Prior to this, Indeg worked for a HEOR consultancy for >5 years.

Holds an MSc in Health Economics and Decision Modelling from the University of Sheffield

And a BSc in Mathematics and Philosophy from the University of Sheffield.

Experience in range of therapy areas:

Oncology (multiple myeloma, ovarian, breast)
Crohn’s Disease
Myelofibrosis
Rare/orphan diseases, including Spinal Muscular Atrophy
Peanut allergy

FIECON exceeds my expectations by genuinely trying to achieve the best outcomes for our company. Their flexibility to adapt to unexpected changes and apply technical rigour, while respecting the commercial focus of the company is unparalleled. We see FIECON as part of our extended team.”

Senior Market Access Manager, Mid-sized Pharma

It was brilliantly smart and very well explained. It seems obvious now but that is what genius is, making complex things appear simple.”

Associate Director, Mid-sized Pharma

FIECON are my go to trusted partner. The team deliver high-quality work to timeline, every time. But more than this, FIECON has worked as part of our team, working towards achieving the best possible outcome by providing high level strategic input and challenge during our discussions.”

Market Access Director, Small Biotech

FIECON’s highly skilled expert team helped us to successfully tackle a number of tough pricing and access challenges. Apart from their flawless technical expertise, we have a reliable thought partner to pressure test new ideas and strategies that have a broader relevance than purely health economic aspects.”

Disease Area Director, Big Pharma

The pricing and market access research was a high quality work project, which included detailed information to define the overall and country strategy while the gap analysis was instrumental in the next steps preparation. ”

Executive Director, Biotech

FIECON’s strategic approach to problem solving is a breath of fresh air. We highly value their HTA knowledge and expertise, and they consistently deliver the best solution for us.”

Value Demonstration & Access Lead, Big Pharma

It is a pleasure to work with FIECON. The team are passionate about what they do and it really shows in their high-quality, creative solutions. Working with FIECON gives your projects the highest chance of success.”

Senior Vice President, Small Biotech

FIECON’s team is highly experienced, commercially focused, responsive and flexible. A particular strength I highlight is that FIECON’s team becomes a true partner with all company functions that they interact with. ”